A Phase 2b trial testing the ability of IRLAB Therapeutics’ investigational oral therapy pirepemat to reduce falls in people with Parkinson’s disease is now expected to complete enrollment by September. Recruitment began last May and was initially expected to finish by the end of 2023, but the…
News
A once-daily treatment with GT-02287, an oral medication being developed by Gain Therapeutics, protected nerve cells from damage and rescued motor symptoms in a mouse model of Parkinson’s disease associated with mutations in the GBA gene. “We believe the data showing complete…
The department of neurology at Vanderbilt University Medical Center (VUMC) is now part of the CurePSP Center of Care network, which works to enhance public awareness and advance research to better understand atypical parkinsonism. The network focuses on three neurodegenerative diseases: progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and…
People with Parkinson’s disease who are given deep brain stimulation (DBS) tend to have more stable long-term life quality and motor function than do patients treated with medications only, according to a new study. Deep brain stimulation, called DBS for short, is a surgical treatment for Parkinson’s disease…
The first patient has been dosed, and the observation period completed, in a clinical trial in China that’s testing iRegene Therapeutics’ NouvNeu001 cell therapy for moderate to advanced Parkinson’s disease. The Phase 1/2 clinical trial (NCT06167681) started in early January at Beijing Hospital, following a green light from the…
People with epilepsy are at more than double the risk of developing Parkinson’s disease than people without epilepsy, but a cause-and-effect relationship has yet to be established, according to a large study by researchers in South Korea. “To the best of our knowledge, there are three case-control studies ……
The virus that causes COVID-19 is able to infect dopamine-producing brain cells and trigger a specific pattern of dysfunction that has been linked with the development of Parkinson’s disease, a study reports. “Given our findings, we posit that over the coming years, there is a need to closely monitor…
Vaxxinity has entered into a research collaboration with the University of Florida to advance the development of vaccines for neurodegenerative diseases, including Parkinson’s disease. Funded by a grant from the state of Florida, the partnership aims to advance Vaxxinity’s lead immunotherapy candidates, designed to prevent and manage…
A new dual-target, adaptive deep brain stimulation (DBS) protocol may offer more clinical benefits for patients than does traditional DBS for Parkinson’s disease, according to newly published data from a small clinical trial. DBS surgery — in which a small device is implanted in the brain to deliver…
Topline data from a Phase 3 clinical trial of buntanetap in early-stage Parkinson’s disease patients is expected soon, according to Annovis Bio, the therapy’s developer. Initially planned for the end of January, ongoing analysis to ensure “clean data” that are accurate and reliable was cited as the reason…
Recent Posts
- Blocking 2 proteins could slow Parkinson’s progression: Study
- How to minimize stress while traveling with Parkinson’s disease
- New PET tracer helps scientists ‘see’ Parkinson’s toxic protein clumps
- Tech duo to advance brain-penetrating drugs for CNS disorders
- New trial offers extended buntanetap access for people with Parkinson’s